Form 4: Neumora Therapeutics Executive Reprices Stock Options

Robert A. Lenz, Head of R&D at Neumora Therapeutics, repriced stock options on February 13, 2025, pending stockholder approval.

Summary

• Robert A. Lenz, Head of R&D at Neumora Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On February 13, 2025, Lenz repriced two stock option grants.
• The first repriced option involves 502,934 shares, initially with an exercise price of $17, now repriced to $1.69.
• The second repriced option covers 100,000 shares, initially with an exercise price of $18.07, also repriced to $1.69.
• The repricing is contingent upon stockholder approval and requires Lenz to remain in service through August 13, 2026.
• The options vest over time, with 25% vesting on the first anniversary of the Vesting Commencement Date and the remainder vesting monthly thereafter.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The repricing could be seen as positive for incentivizing the executive, but it also depends on stockholder approval and continued service. There are no explicit positive or negative statements about the company's overall performance.

Positives

• The repricing of stock options may incentivize Robert A. Lenz to remain with Neumora Therapeutics.
• The lower exercise price of $1.69 could make the options more attractive to Lenz.

Negatives

• The repricing is contingent on stockholder approval, which introduces uncertainty.
• The repricing is also contingent on Lenz remaining in service through August 13, 2026, which may not be guaranteed.

Risks

• Failure to obtain stockholder approval would void the repricing.
• If Robert A. Lenz leaves the company before August 13, 2026, the repricing may not be effective.
• The repricing could be perceived negatively by some stockholders if they believe it unduly benefits the executive.

Future Outlook

The repricing is contingent upon stockholder approval and Robert A. Lenz's continued service through August 13, 2026. If these conditions are met, the repriced options will be in effect.

Industry Context

Stock option repricing is a tool companies use to incentivize employees, especially when the stock price has declined. It's common in the biotech industry to retain key personnel.

Comparison to Industry Standards

• Stock option repricing is a common practice in the biotechnology industry, particularly for companies that have experienced a decline in stock price.
• Companies like Biogen and Amgen have used similar strategies to retain key employees during periods of volatility.
• The specific terms of the repricing, such as the new exercise price and vesting schedule, are generally tailored to the individual circumstances of the company and the employee.

Stakeholder Impact

• Shareholders will need to vote on the option repricing.
• Employees may view the repricing as a positive sign of the company's commitment to retaining talent.
• The repricing could impact the company's financial statements due to changes in stock-based compensation expense.

Next Steps

• Neumora Therapeutics needs to obtain stockholder approval for the option repricing.
• Robert A. Lenz needs to remain in service through August 13, 2026, for the repricing to remain effective.

Key Dates